SEQUENT SCIENTIFIC share price has zoomed 10% and is presently trading at Rs 138.0.
Meanwhile, the BSE HEALTHCARE index is at 38,437.4 (down 0.4%).
Among the top gainers in the BSE HEALTHCARE index today are SUVEN PHARMACEUTICALS (up 4.7%) and ALEMBIC PHARMA (up 2.9%).
Cadila Healthcare (down 1.6%) and AJANTA PHARMA (down 1.6%) are among the top losers today.
Over the last one year, SEQUENT SCIENTIFIC has moved up from Rs 87.4 to Rs 138.0, registering a gain of Rs 50.6 (up 57.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,922.2 to 38,437.4, registering a gain of 48.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 107.9%), Lupin (up 101.8%) and Cadila Healthcare (up 99.9%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,796.5 (down 0.2%).
The top losers among the BSE Sensex today are Nestle (down 1.8%) and NTPC (down 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Power Grid Corp..
In the meantime, NSE Nifty is at 24,297.9 (down 0.1%). Nestle and NTPC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,344.2 to 79,796.5, registering a gain of 14,452.4 points (up 22.1%).
SEQUENT SCIENTIFIC net profit grew 101.4% YoY to Rs 13 million for the quarter ended March 2024, compared to a loss of Rs 924 million a year ago. Net sales declined 1.5% to Rs 3,612 million during the period as against Rs 3,667 million in January-March 2023.
For the year ended March 2023, SEQUENT SCIENTIFIC reported 372.5% decrease in net profit to Rs -1,220 million compared to net profit of Rs 448 million during FY22. Revenue of the company grew 0.6% to Rs 14,209 million during FY23.
The current Price to earnings ratio of SEQUENT SCIENTIFIC, based on rolling 12 month earnings, stands at -116.3.
Equitymaster requests your view! Post a comment on "SEQUENT SCIENTIFIC Gains 10%; BSE HEALTHCARE Index Down 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!